Insight Molecular Diagnostics (IMDX) KOL event summary

Introduction and agenda

• The session focused on advances in donor-derived cell-free DNA (dd-cfDNA) testing for heart transplant surveillance, featuring a fireside chat and Q&A with a leading transplant cardiologist.

• Discussion included the evolution of transplant monitoring, current protocols, and the potential impact of new in-house dd-cfDNA assays.

KOL background and credentials

• Dr. Max Liebo, a transplant cardiologist at Loyola University, has over a decade of experience using molecular surveillance in heart transplant patients.

• He has participated in major registries and has experience with multiple dd-cfDNA products.

Market insights and analysis

• Heart transplant rejection surveillance has shifted from frequent invasive biopsies to non-invasive molecular assays over the past decade.

• Recent guidelines and literature increasingly support dd-cfDNA as a primary tool for rejection monitoring.

• Adoption barriers include logistical challenges, inertia in protocol updates, and the need for more real-world data.